- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07570355
Pterygopalatine Ganglion Stimulation for the Treatment of Geographic Atrophy
Feasibility and Safety Evaluation of Pterygopalatine Ganglion Stimulation in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Controlled Pilot Study
The goal of this clinical trial is to evaluate the feasibility and safety of pterygopalatine ganglion (PPG) stimulation in adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
The main questions it aims to answer are:
Is PPG stimulation feasible to implement, as reflected by participant adherence to the intervention and completion of follow-up assessments? Is PPG stimulation safe, as assessed by the incidence of adverse events and clinical ophthalmic examinations? What are the preliminary effects of PPG stimulation on choroidal perfusion, retinal sensitivity, visual acuity, and the progression of GA lesion area?
Researchers will compare active PPG stimulation with sham stimulation (a procedure that mimics the intervention without delivering real stimulation) to assess feasibility and safety, while exploring potential therapeutic effects.
Participants will:
Receive active or sham PPG stimulation according to randomization over a 12-month study period Attend scheduled clinic visits for safety monitoring and multimodal ophthalmic assessments Undergo examinations including optical coherence tomography (OCT), fundus autofluorescence imaging, microperimetry, and visual acuity testing
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Xiehe Kong, MD
- Número de telefone: 021-13621775647
- E-mail: ynomrahkong@163.com
Locais de estudo
-
-
-
Shanghai, China, 200030
- Shanghai Research Institute of Acupuncture and Meridian
-
Contato:
- Xiehe Kong, MD
- Número de telefone: 021-13621775647
- E-mail: ynomrahkong@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Best-corrected visual acuity (BCVA), as measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, ranging from 25 to 80 letters (Snellen equivalent, 20/320 to 20/25).
A confirmed diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), with no involvement of the foveal center. Fundus autofluorescence (FAF) imaging must demonstrate a total GA area of 2.5 to 17.5 mm² located within a 30° field centered on the fovea, with the presence of any pattern of increased autofluorescence at the junctional zone of GA. In cases of multifocal GA, at least one lesion must be ≥1.25 mm² in size.
- If both eyes meet the eligibility criteria, the eye with the worse BCVA will be selected as the study eye. If BCVA is equal in both eyes, the right eye will be designated as the study eye.
Exclusion Criteria:
- History or evidence of submacular surgery or other treatments for AMD in the study eye, with the exception of oral vitamin and mineral supplementation.
- History of intraocular surgery within 3 months prior to screening, or the presence of ocular conditions requiring surgical intervention during the study period.
- Receipt of any periocular or intravitreal injection therapy in the study eye within 3 months prior to screening.
- History or evidence of choroidal neovascularization in either eye, or the presence of any other retinal disease that may confound the assessment of macular structure or function (e.g., diabetic retinopathy or pathologic myopia).
- Presence of severe systemic disease or any other condition deemed unsuitable for study participation.
- Inability to comply with scheduled visits or complete study procedures due to cognitive impairment or other factors, as judged by the investigator.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Falso: Estimulação simulada
|
During sham stimulation, a disposable stainless steel needle (0.25 × 25 mm) was inserted superficially at the same anatomical location as in the active stimulation group, to a depth of approximately 2 cm.
Ultrasound guidance was applied in an identical manner to that used in the active intervention to mimic the procedural experience.
However, the internal circuitry of the stimulation device was disconnected to prevent current delivery.
The device interface continued to display real-time parameters, including current intensity, frequency, and stimulation duration, thereby maintaining the appearance of active operation.
Outros nomes:
|
|
Experimental: Estimulação ativa
|
Electrical stimulation was delivered using a disposable sterile needle electrode (0.30 × 60 mm; Beijing Keyuan Medical Devices Co., Ltd., China).
Under ultrasound guidance, the needle tip was advanced into the pterygopalatine fossa.
Ipsilateral pterygopalatine ganglion stimulation was administered to the study eye using an intermittent waveform at a frequency of 5 Hz and a current intensity of 1-2 mA for 10 minutes.
The stimulation intensity was adjusted to elicit a mild local electrical sensation as perceived by the participant.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of participants who completed the trial
Prazo: At 12 months
|
Proportion of participants who were successfully randomized to either intervention group, fully adhered to the assigned intervention protocol, and completed all scheduled follow-up assessments.
|
At 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of adverse events
Prazo: From enrollment to 12 months
|
From enrollment to 12 months
|
|
|
Choroidal structure
Prazo: -7 to 0 days, 1, 3, 6, 9, and 12 months
|
-7 to 0 days, 1, 3, 6, 9, and 12 months
|
|
|
Retinal sensitivity
Prazo: Baseline (0), 6 months, and 12 months
|
Baseline (0), 6 months, and 12 months
|
|
|
Standard and low-luminance best corrected visual acuity
Prazo: -7 to 0 days, 1, 3, 6, 9, and 12 months
|
-7 to 0 days, 1, 3, 6, 9, and 12 months
|
|
|
Geographic atrophy lesion area and square root-transformed geographic atrophy area
Prazo: -7 to 0 days, 6 months, and 12 months
|
-7 to 0 days, 6 months, and 12 months
|
|
|
Contrast sensitivity
Prazo: Baseline (0), 1, 3, 6, 9, and 12 months
|
Baseline (0), 1, 3, 6, 9, and 12 months
|
|
|
25-item National Eye Institute Visual Function Questionnaire score
Prazo: Baseline (0), 6 months, and 12 months
|
Vision-related quality of life was assessed using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25).
This corresponds to a score between 0 and 100, with higher scores indicating better visual quality of life
|
Baseline (0), 6 months, and 12 months
|
|
Treatment credibility scale score
Prazo: 1 week and 12 months
|
Assessed by asking participants to rate their response to five questions on a 10-point treatment credibility scale developed by Borkovec and Nau.
Higher scores represent higher expectations of efficacy.
|
1 week and 12 months
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ShanghaiIAMM2026011
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Pterygopalatine ganglion stimulation
-
Yonsei UniversityDesconhecidoEstado da doença do trato pancreatobiliar, (especialmente quem precisa se submeter a pancreatoduodenectomia)Republica da Coréia
-
University of MinnesotaThe Foundation for the Advancement of Clinical TMSRecrutamento
-
US Department of Veterans AffairsConcluídoDoença cardiovascular | Lesão da medula espinalEstados Unidos
-
University of New MexicoNational Institute of Mental Health (NIMH); University of Texas Southwestern... e outros colaboradoresConcluído
-
Kaohsiung Medical University Chung-Ho Memorial...Concluído
-
Abbott Medical DevicesConcluídoTranstorno Depressivo MaiorIsrael, França, Reino Unido
-
Bezmialem Vakif UniversityRecrutamentoCirurgia Bimaxilar | Bloqueio do Gânglio EsfenopalatinoPeru
-
Centre Hospitalier St AnneRecrutamentoIsso já está em portuguêsFrança
-
RS MedicalAccelerated Care Plus; Research Institute of Health and Science (RIHSE)ConcluídoOsteoartrite do joelhoJapão
-
University of ManitobaRecrutamentoDemência; Degenerativa, demência misturadaCanadá